14 completed, 5 unknown, 3 not yet recruiting, 1 active not recruiting. 13 Not applicable, 7 Phase 1, 7 Phase 2, 1 Phase 3.
Follow Appointments and Schedules: new trials by email Literature Review of Appointments and Schedules trials Research Report on Appointments and Schedules
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes AI-BRIDGE, Educational Materials - Diabetic Retinopathy, Diabetes Mellitus | Not applicable | Not yet recruiting | University of Wisconsin, Madison | 6900 | 2026-10-01 | 2026-10-02 |
| Neuromodulation Strategies for Treatment-Resistant Essential Tremor Using Chronos™ DBS Continuous, Continuous + High Frequency Cycling, High Frequency - Essential Tremor | Not applicable | Not yet recruiting | University of British Columbia | 5 | 2026-04-01 | 2025-12-24 |
| Comparison of Mastectomy Expander Trial intervention (unilateral/bilateral), scheduled for (NSME/SSME), indication (breast cancer diagnosis (malignancy) with neoadjuvant chemotherapy or DCIS diagnosis without neoadjuvant chemotherapy - Mastectomy and Breast Reconstruction, Tissue Expander Based Breast Reconstruction | Not applicable | Not yet recruiting | Medical University Innsbruck | 80 | 2026-03-01 | 2026-02-25 |
| Comparing Hepatitis B Vaccination Schedules in Patients on Hemodialysis Recombinant Hepatitis B Vaccine - 3-Dose Schedule, Recombinant Hepatitis B Vaccine - 4-Dose Schedule - Hepatitis B, ESRD (End Stage Renal Disease) | Not applicable | Completed | Jinnah Hospital | 104 | 2025-12-10 | 2026-08-25 |
| Community Support Program for Lung Cancer Screening Volume II Transportation, Scheduling - Lung Cancer | Not applicable | Completed | Abramson Cancer Center at Penn Medicine | 252 | 2024-10-01 | 2026-03-24 |
| Fixed-Interval vs. On-Demand Analgesia After Vacuum-Assisted Delivery: RCT Scheduled Pain relief drugs administered during the first 24 hours postpartum every 8 hours., On demand analgesia - Vacuum-assisted Deliveries | Not applicable | Completed | Yael Yagur | 51 | 2024-09-21 | 2026-04-16 |
| Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors RP-3467 at assigned dose and schedule, Olaparib 200-300 mg BID, daily - Advanced Solid Tumor | Phase 1 | Terminated | Repare Therapeutics | 26 | 2024-09-17 | 2026-01-16 |
| Safety and Efficacy of AR1005 in Patients with Lewy Body Disease AR1005, Placebo, Rivastigmine 3 mg - Lewy Body Dementia | Phase 2 | Unknown | Yonsei University | 60 | 2024-01-01 | 2024-10-02 |
| Phase II Clinical Trial of the Inactivated Rotavirus Vaccine IRV on a 0- and 28-day schedule, IRV on a 0-, 28- and 56-day schedule, Placebo on Day 0, 28 - Rotavirus Infections, Diarrhea | Phase 2 | Unknown | Institute of Medical Biology, Chinese Academy of Medical Sciences | 600 | 2023-10-20 | 2024-01-03 |
| Time Restricted Eating (TRE) Among Endometrial Cancer Patients Time Restricted Eating (TRE) Schedule - Endometrial Cancer | Not applicable | Unknown | University of Utah | 15 | 2021-10-07 | 2023-11-30 |
| Effect of Rate (Slope) of Compression on the Incidence of Symptomatic ETD and MEB: a Phase III Prospective Study. Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw), Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw) - Ear Barotrauma, Middle Ear Disease | Not applicable | Completed | Northwell Health | 1553 | 2021-10-01 | 2026-06-09 |
| Impact of 5-Fluorouracil (5-FU) on Cancer Cells From Liver Metastases of Colon Cancer Scheduled and planned surgery - Cancer of Colon, Metastasis to Liver | Withdrawn | Centre Leon Berard | 2021-06-01 | 2024-02-14 | ||
| Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity mRNA-1273 SARS-CoV-2 vaccine, BNT162b2, ChAdOx1-S [recombinant] - COVID-19 | Phase 2 | Active not recruiting | Canadian Immunization Research Network | 669 | 2021-05-20 | 2025-03-18 |
| Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer Time Restricted Eating (TRE) Schedule, Control Schedule - Endometrial Neoplasms | Not applicable | Completed | University of Utah | 39 | 2021-02-18 | 2026-07-29 |
| Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant Viral Specific T-cells (VSTs) Scheduled, Viral Specific T-cells (VSTs) Treatment - Allogeneic Stell Cell Transplant, Viral Infection | Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 180 | 2021-01-27 | 2026-09-04 |
| Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus Infection Low dosage IRV on a 0- and 28-day schedule, Medium dosage IRV on a 0- and 28-day schedule, High dosage IRV on a 0- and 28-day schedule - Rotavirus Infection | Phase 1 | Unknown | Chinese Academy of Medical Sciences | 32 | 2020-12-03 | 2020-12-10 |
| Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule, Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule, High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule - COVID-19 | Phase 1 / Phase 2 | Completed | Institute of Medical Biology, Chinese Academy of Medical Sciences | 471 | 2020-07-10 | 2023-10-11 |
| Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule, Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule, Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule - COVID-19 | Phase 1 / Phase 2 | Completed | Institute of Medical Biology, Chinese Academy of Medical Sciences | 942 | 2020-05-15 | 2023-10-11 |
| Syndemics and Loss from the HIV Care Continuum in India - Intervention Active outreach, Appointments, Financial support - HIV Infections | Not applicable | Completed | Brigham and Women's Hospital | 50 | 2019-06-20 | 2025-02-12 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule - Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Completed | Juno Therapeutics, a Subsidiary of Celgene | 387 | 2016-01-06 | 2024-06-27 |
Showing 20 of 27. Sign in to see all of them.
COVID-19 (3) · Hepatitis B (3) · Endometrial Neoplasms (2) · HIV Infections (2) · Hepatitis C (2) · Rotavirus Infections (2) · Acquired Immunodeficiency Syndrome (1) · Bronchiolitis Obliterans Syndrome (1) · Colonic Neoplasms (1) · Diabetes Mellitus (1) · Diabetic Retinopathy (1) · Diarrhea (1) · Disease (1) · Ear Diseases (1) · Essential Tremor (1)
Institute of Medical Biology, Chinese Academy of Medical Sciences (3) · University of Utah (2) · AbbVie (prior sponsor, Abbott) (1) · Abramson Cancer Center at Penn Medicine (1) · Brigham and Women's Hospital (1) · Canadian Immunization Research Network (1) · Centre Hospitalier Universitaire de Besancon (1) · Centre Leon Berard (1) · Children's Hospital Medical Center, Cincinnati (1) · Chinese Academy of Medical Sciences (1) · Institut de Recherche pour le Developpement (1) · Jinnah Hospital (1) · Juno Therapeutics, a Subsidiary of Celgene (1) · Mansoura University (1) · Medical University Innsbruck (1)
United States (11) · China (4) · Canada (2) · Egypt (1) · France (1) · India (1) · Israel (1) · Mexico (1) · Pakistan (1) · South Korea (1) · Thailand (1)
Mary Playdon, PhD, MPH (2) · Qin Yu (2) · Xiaoqiang Liu (2) · Byoung Seok Ye, MD, PhD (1) · David Dayya, DO, PhD, MPH (1) · David I Laibson, Ph.D (1) · Farouk Dako, MD (1) · Felix Vilchez, MD-PhD (1) · Gonzague Jourdain, MD. PhD (1) · Hongjun Li, Ph.D (1) · Joanne Langley (1) · Kyle Holen (1) · Lu-Yu Hwang, MD (1) · Mohamed R El Tahan, MD (1)
PMID 20936979, PMID 22075088, PMID 22170543, PMID 23152368, PMID 24631093, PMID 26420235, PMID 31605294, PMID 32888407, PMID 33165503, PMID 33720336, PMID 33875266, PMID 33904895, PMID 33970454, PMID 34125421, PMID 34310745, PMID 34493319, PMID 34515338, PMID 35156195, PMID 35337365, PMID 35610089, PMID 36208351, PMID 36755418, PMID 36971688, PMID 37890149, PMID 38072625, PMID 38796326, PMID 42237652, PMID 42733081
P30AG034532 (1), R01EY035994 (1), UL1TR002538 (1)